on MAAT PHARMA (isin : FR0012634822)
MaaT Pharma General Meeting: Results and Appointments
At the Annual and Extraordinary General Meeting of June 20, 2025, MaaT Pharma, a biotechnology company specializing in Microbiome Ecosystem Therapies™, achieved a quorum of over 73%. Shareholders approved the majority of resolutions, with over 99% of votes in favor, with the exception of resolutions 29 and 34, which received approximately 69% approval.
The 2024 financial statements and the 2025 remuneration policy were validated. A delegation resolution for merger transactions was accepted, while a capital increase proposal for a savings plan was rejected.
Mr. Jean-Marie Lefèvre was appointed Chairman, succeeding Mr. Karim Dabbagh. The liquidity contract with Kepler Cheuvreux is maintained, in accordance with resolutions 19 and 20.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAAT PHARMA news